These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31427953)

  • 1. Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.
    Taniguchi Y; Yamamoto M; Ikushima H; Ohara S; Takeshima H; Sakatani T; Usui K
    Case Rep Oncol; 2019; 12(2):564-567. PubMed ID: 31427953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.
    Baglivo S; Mandarano M; Bellezza G; Minotti V; Bonaiti A; Fischer MJ; Birocchi I; Roila F; Metelli N; Ludovini V; Metro G
    Oncol Ther; 2022 Jun; 10(1):291-300. PubMed ID: 35066813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
    Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
    Miyawaki E; Murakami H; Mori K; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Takahashi T
    Jpn J Clin Oncol; 2020 May; 50(5):617-622. PubMed ID: 32211792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
    An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
    Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
    Uenami T; Ishijima M; Kanazu M; Kurebe H; Edahiro R; Nishida K; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Ann Transl Med; 2018 Nov; 6(22):444. PubMed ID: 30596074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
    Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
    Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
    BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression.
    Tozuka T; Seike M; Minegishi Y; Kitagawa S; Kato T; Takano N; Hisakane K; Takahashi S; Kobayashi K; Kashiwada T; Sugano T; Takeuchi S; Kunugi S; Noro R; Saito Y; Kubota K; Gemma A
    Onco Targets Ther; 2018; 11():5601-5605. PubMed ID: 30237726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
    Yamamoto Y; Kodama K; Maniwa T; Takeda M
    J Cardiothorac Surg; 2017 Nov; 12(1):98. PubMed ID: 29169381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Chan RT
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():7-9. PubMed ID: 29508940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor.
    Chen LC; Shih JY; Yu CJ; Yang CY
    Respirol Case Rep; 2019 Jul; 7(5):e00425. PubMed ID: 31007929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib for the treatment of metastatic non-small cell lung cancer.
    Joshi M; Rizvi SM; Belani CP
    Cancer Manag Res; 2015; 7():75-82. PubMed ID: 25733926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
    Levy B; Paz-Ares L; Bennouna J; Felip E; Abreu DR; Isla D; Barlesi F; Molinier O; Madelaine J; Audigier-Valette C; Kim SW; Kim HR; Ozguroglu M; Erman M; Badin FB; Mekhail TM; Scheff R; Chisamore MJ; Sadrolhefazi B; Riess JW
    Clin Lung Cancer; 2019 May; 20(3):e407-e412. PubMed ID: 30808583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of uncommon
    Zhang T; Wan B; Zhao Y; Li C; Liu H; Lv T; Zhan P; Song Y
    Transl Lung Cancer Res; 2019 Jun; 8(3):302-316. PubMed ID: 31367543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups.
    Zhang Q; Cui Y; Zhang J; Kenjiabieke J; Aerxiding P
    Exp Ther Med; 2020 Jun; 19(6):3513-3520. PubMed ID: 32346412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.